Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT07040644 Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT07040644
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are female and aged 18 or older.
  • People who have been diagnosed with triple-negative breast cancer (a specific type of breast cancer), confirmed through a tissue or cell sample.
  • People whose cancer cannot be surgically removed, or has spread to other parts of the body.
  • People whose cancer tests positive for a protein called PD-L1 (measured by a score of 1 or higher, as determined by a central laboratory).
  • People who have not yet received any systemic (whole-body) treatment for their advanced or metastatic breast cancer.
  • People who have at least one area of cancer that can be measured on a scan, according to standard medical guidelines.
  • People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
  • People whose blood counts and liver and kidney function are within acceptable ranges.
  • People who are willing to sign a form confirming they understand and agree to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously been treated with certain types of immune checkpoint medicines (anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapies).
  • People who have active cancer that has spread to the brain or spinal cord.
  • People who have an active autoimmune disease, or a history of an autoimmune condition that needed treatment affecting the whole body.
  • People who have an active infection that currently requires treatment affecting the whole body.
  • People who are pregnant or currently breastfeeding.
  • People who have had another active cancer that has required treatment within the past 5 years.
  • People who have had a serious allergic reaction to any of the medicines used in this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov